Cerebellar atrophy in epileptic patients

Area of Science:

• Neurology
• Radiology
• Pharmacology

Background:

• Epilepsy is a neurological disorder characterized by recurrent seizures.
• Phenytoin (PHT) is a commonly prescribed antiepileptic drug.
• Potential neurotoxic effects of long-term antiepileptic drug use require investigation.

Purpose of the Study:

• To investigate the incidence and potential causes of cerebellar and brainstem (CBS) atrophy in epileptic patients.
• To assess the relationship between phenytoin (PHT) treatment and CBS atrophy.
• To determine factors associated with CBS atrophy, including treatment duration, dosage, and seizure characteristics.

Main Methods:

• High-resolution CT scans of the brain and posterior fossa were conducted on 106 PHT-treated epileptics, 28 de novo epileptics, and 43 controls.
• Patients were categorized based on CT findings (normal, cerebral and CBS atrophy, pure CBS atrophy).
• Statistical analysis correlated atrophy with age, illness duration, seizure history, and cumulative PHT dosage.

Main Results:

• Chronic PHT or PHT+phenobarbital treatment was associated with a higher incidence of CBS atrophy compared to controls and de novo epileptics.
• Moderate to severe CBS atrophy was exclusively observed in chronically treated patients.
• Posterior fossa atrophy significantly correlated with longer illness duration and higher cumulative PHT dose, but not with seizure frequency.

Conclusions:

• Long-term phenytoin treatment may lead to cerebellar and brainstem atrophy in epileptic patients.
• The degree of atrophy is associated with the duration of treatment and total PHT exposure.
• Seizure frequency does not appear to be a contributing factor to PHT-induced CBS atrophy.